Middle East African Journal of Ophthalmology

LETTER TO EDITOR
Year
: 2019  |  Volume : 26  |  Issue : 1  |  Page : 53-

Authors' Reply


Justin D Pennington, R Joel Welch, Sara E Lally, Jerry A Shields, Ralph C Eagle, Carol L Shields 
 Ocular Oncology Service and Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA

Correspondence Address:
Dr. Carol L Shields
Ocular Oncology Service, 840 Walnut Street, Suite 1440, Philadelphia, PA
USA




How to cite this article:
Pennington JD, Welch R J, Lally SE, Shields JA, Eagle RC, Shields CL. Authors' Reply.Middle East Afr J Ophthalmol 2019;26:53-53


How to cite this URL:
Pennington JD, Welch R J, Lally SE, Shields JA, Eagle RC, Shields CL. Authors' Reply. Middle East Afr J Ophthalmol [serial online] 2019 [cited 2019 Nov 21 ];26:53-53
Available from: http://www.meajo.org/text.asp?2019/26/1/53/256989


Full Text

Sir,

We thank the author for the insightful comments on the potential relationship of HIV with rhabdomyosarcoma. In our case, prior to commencing chemotherapy, the patient's immune status was carefully examined and our patient was HIV negative. We agree that the overlap between cancer and the immune system is fertile ground for our understanding of the pathogenesis, progression, and possible cure of cancer.[1,2]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects. Retina 2018;38:1063-78.
2Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA, et al. Conjunctival tumors: Review of clinical features, risks, biomarkers, and outcomes - The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila) 2017;6:109-20.